Naming Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Naming Wu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Juan Tao
Department of Dermatology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST) Wuhan China
2 shared publications - Jun Li
Department of Dermatology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publications Chen Shen
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan 430022, China
1 shared publication- Enzhu Dong
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Hubei Engineering Research Center for Skin Repair and Theranostics, Wuhan, China
1 shared publication Fang Zheng
Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China
1 shared publication- Jinjin Zhu
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Hubei Engineering Research Center of Skin Disease Theranostics and Health, Wuhan, Hubei, China
1 shared publication
Latest Publications
- Open Access
- 10 April 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (11) , 2828-2838.e10
Tolerogenic Monocyte-Derived Langerhans Cells Promote Melanoma Progression and Immunotherapy Resistance through Aryl Hydrocarbon Receptor–Cyclooxygenase-2 Activation
- 10 April 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (11) , 2828-2838.e10
Open AccessTolerogenic Monocyte-Derived Langerhans Cells Promote Melanoma Progression and Immunotherapy Resistance through Aryl Hydrocarbon Receptor–Cyclooxygenase-2 Activation
- Open Access
- 4 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (40)
MerTK + macrophages promote melanoma progression and immunotherapy resistance through AhR-ALKAL1 activation
Despite our increasing understanding of macrophage heterogeneity, drivers of macrophage phenotypic and functional polarization in the microenvironment are not fully elucidated. Here, our single-cell RNA sequencing data identify a subpopulation of macrophages expressing high levels of the phagocytic receptor MER proto-oncogene tyrosine kinase (MerTK + macrophages), which is closely associated with melanoma progression and immunotherapy resistance. Adoptive transfer of the MerTK + macrophages into recipient mice notably accelerated tumor growth regardless of macrophage depletion. Mechanistic studies further revealed that ALK And LTK Ligand 1 (ALKAL1), a target gene of aryl hydrocarbon receptor (AhR), facilitated MerTK phosphorylation, resulting in heightened phagocytic activity of MerTK + macrophages and their subsequent polarization toward an immunosuppressive phenotype. Specifically targeted delivery of AhR antagonist to tumor-associated macrophages with mannosylated micelles could suppress MerTK expression and improved the therapeutic efficacy of anti–programmed cell death ligand 1 therapy. Our findings shed light on the regulatory mechanism of MerTK + macrophages and provide strategies for improving the efficacy of melanoma immunotherapy.
- 4 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (40)
Open AccessMerTK + macrophages promote melanoma progression and immunotherapy resistance through AhR-ALKAL1 activation
Despite our increasing understanding of macrophage heterogeneity, drivers of macrophage phenotypic and functional polarization in the microenvironment are not fully elucidated. Here, our single-cell RNA sequencing data identify a subpopulation of macrophages expressing high levels of the phagocytic receptor MER proto-oncogene tyrosine kinase (MerTK + macrophages), which is closely associated with melanoma progression and immunotherapy resistance. Adoptive transfer of the MerTK + macrophages into recipient mice notably accelerated tumor growth regardless of macrophage depletion. Mechanistic studies further revealed that ALK And LTK Ligand 1 (ALKAL1), a target gene of aryl hydrocarbon receptor (AhR), facilitated MerTK phosphorylation, resulting in heightened phagocytic activity of MerTK + macrophages and their subsequent polarization toward an immunosuppressive phenotype. Specifically targeted delivery of AhR antagonist to tumor-associated macrophages with mannosylated micelles could suppress MerTK expression and improved the therapeutic efficacy of anti–programmed cell death ligand 1 therapy. Our findings shed light on the regulatory mechanism of MerTK + macrophages and provide strategies for improving the efficacy of melanoma immunotherapy.